The overall goal of Project 1 (Clinical Studies) is to identity the clinical, immunologic, virologic and epidemiologic factors that have the strongest influence on determining the ultimate clinical manifestations of dengue virus infections in Thai children. This project will involve two clinical studies. The first will be a prospective study in Bangkok of symptomatic children hospitalized with acute dengue illness to define the pathophysiology of severe dengue. The findings of this study should be useful to guide the evaluation and triage of febrile patients with suspected dengue as well as to improve the assessment of capillary leakage in DHF. We plan to utilize noninvasive technologies such as echocardiogram, ultrasonography, and measures of heart rate variability. Novel near infrared spectroscopy will be used to noninvasively determine hematocrit, muscle pH and muscle pO2. We also will perform flow cytometric assays to identify and characterize circulating endothelial cells as well as virus-specific T cells during acute infection. Our second study will involve a Phase lib vaccine efficacy trial that will take place in Kamphaeng Phet, Thailand. Research studies conducted during this unique opportunity will analyze the effects of dengue vaccination on viral transmission and define immunologic correlates of protection or possible sensitization to more severe illness. These research studies would not be performed by the vaccine manufacturer and will be crucial for the design and implementation of future clinical field trials of dengue vaccines. These clinical studies will be supported by Cores A and B and will provide valuable specimens (serum, peripheral blood mononuclear cells and virus isolates) for studies to be performed in Project 2.
This Project includes two clinical studies in Thailand: (1) in hospitalized children, how the mosquito-borne dengue virus causes clinical disease and (2) in a field trial of a candidate dengue vaccine, to study how vaccines may protect against dengue virus infection.
| Park, Sangshin; Srikiatkhachorn, Anon; Kalayanarooj, Siripen et al. (2018) Use of structural equation models to predict dengue illness phenotype. PLoS Negl Trop Dis 12:e0006799 |
| Salje, Henrik; Cummings, Derek A T; Rodriguez-Barraquer, Isabel et al. (2018) Reconstruction of antibody dynamics and infection histories to evaluate dengue risk. Nature 557:719-723 |
| Kang, Jeon-Young; Aldstadt, Jared (2017) The Influence of Spatial Configuration of Residential Area and Vector Populations on Dengue Incidence Patterns in an Individual-Level Transmission Model. Int J Environ Res Public Health 14: |
| Srikiatkhachorn, Anon; Mathew, Anuja; Rothman, Alan L (2017) Immune-mediated cytokine storm and its role in severe dengue. Semin Immunopathol 39:563-574 |
| Rattanamahaphoom, Jittraporn; Leaungwutiwong, Pornsawan; Limkittikul, Kriengsak et al. (2017) Activation of dengue virus-specific T cells modulates vascular endothelial growth factor receptor 2 expression. Asian Pac J Allergy Immunol 35:171-178 |
| Kalayanarooj, Siripen; Rothman, Alan L; Srikiatkhachorn, Anon (2017) Case Management of Dengue: Lessons Learned. J Infect Dis 215:S79-S88 |
| Moulton, Steven L; Mulligan, Jane; Srikiatkhachorn, Anon et al. (2016) State-of-the-art monitoring in treatment of dengue shock syndrome: a case series. J Med Case Rep 10:233 |
| Srikiatkhachorn, Anon; Yoon, In-Kyu (2016) Immune correlates for dengue vaccine development. Expert Rev Vaccines 15:455-65 |
| Rothman, Alan L; Ennis, Francis A (2016) Dengue Vaccine: The Need, the Challenges, and Progress. J Infect Dis 214:825-7 |
| Townsley, E; O'Connor, G; Cosgrove, C et al. (2016) Interaction of a dengue virus NS1-derived peptide with the inhibitory receptor KIR3DL1 on natural killer cells. Clin Exp Immunol 183:419-30 |
Showing the most recent 10 out of 119 publications
